Drug Trial Radar · NCT00567580
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,792
Actual
Start
Feb 2008
Primary completion
Jul 12, 2018
Sponsor
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Cancer and Leukemia Group B; NRG Oncology
- First posted
- Dec 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen-deprivation therapy is more effective for prostate cancer. PURPOSE: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.
Conditions
- Prostate Cancer
Interventions
PBRTRadiation
1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
PLNRTRadiation
1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.
AADrug
Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
LHRH agonistDrug
Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Free From Progression (FFP) at 5 YearsTime frame: From randomization to five years.
Locations
460 sites in 4 countries. Site status is shown where the registry gives one.
UAB Comprehensive Cancer Center
Birmingham, Alabama
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska
Arizona Center for Cancer Care - Peoria
Peoria, Arizona
Arizona Oncology Services Foundation
Phoenix, Arizona
Arizona Oncology - Tucson
Tucson, Arizona
Auburn Radiation Oncology
Auburn, California
Peninsula Medical Center
Burlingame, California
Radiation Oncology Centers - Cameron Park
Cameron Park, California
Mercy Cancer Center at Mercy San Juan Medical Center
Carmichael, California
East Bay Radiation Oncology Center
Castro Valley, California
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California
Enloe Cancer Center at Enloe Medical Center
Chico, California
Valley Medical Oncology
Fremont, California
Washington Township Hospital
Fremont, California
California Cancer Center - Woodward Park Office
Fresno, California
Cancer Care Associates
Fresno, California
Rebecca and John Moores UCSD Cancer Center
La Jolla, California
Veterans Affairs Medical Center - Long Beach
Long Beach, California
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Providence Holy Cross Cancer Center
Mission Hills, California
Memorial Medical Center
Modesto, California
El Camino Hospital Cancer Center
Mountain View, California
Sutter Health - Western Division Cancer Research Group
Novato, California
Alta Bates Summit Medical Center - Summit Campus
Oakland, California
Bay Area Breast Surgeons, Incorporated
Oakland, California
CCOP - Bay Area Tumor Institute
Oakland, California
Larry G Strieff MD Medical Corporation
Oakland, California
Tom K Lee, Incorporated
Oakland, California
St. Joseph Hospital Regional Cancer Center - Orange
Orange, California
Feather River Hospital Cancer Center
Paradise, California
Radiation Oncology Center - Roseville
Roseville, California
Radiological Associates of Sacramento Medical Group, Incorporated
Sacramento, California
University of California Davis Cancer Center
Sacramento, California
Mercy General Hospital
Sacramento, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
California Pacific Medical Center - California Campus
San Francisco, California
Doctors Medical Center - San Pablo Campus
San Pablo, California
Saint Helena Hospital
St. Helena, California
Showing 40 of 460 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.